Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 19/20 | 1.00 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 1.00 |
| ▸ | KDM5C | P41229 | 2/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 0.66 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.66 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549478 | 0.79 | KDM5A (1.00) | KDM5AKDM5BKDM5CKDM4CKDM6B | |
| Hydrochloric Acid SCHEMBL31236648 | 0.78 | KDM5A (0.98) | KDM5AKDM5BKDM5CKDM4CKDM6B | |
| SCHEMBL17547804 | 0.71 | KDM5A (0.55) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL17547867 | 0.63 | KDM5A (0.46) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16050360 | 0.63 | KDM5A (0.46) | KDM5AKDM5BKDM5CKDM4CKDM6B | |
| SCHEMBL17547865 | 0.62 | KDM5B (0.50) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16050579 | 0.62 | KDM5A (0.45) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL30332210 | 0.62 | PDK2 (0.48) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL17547819 | 0.62 | KDM5A (0.45) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16092351 | 0.62 | KDM5B (0.49) | KDM5AKDM5BKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | claimed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | claimed |
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | KDM5A 4642/4885KDM5B 4560/4885KDM5C 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.